Our vendor and supplier mapping project illustrates the biopharmaceutical industry's investment in our state economies and in the health of the patients we serve.
WA at a Glance
Welcome to We Work For Health Washington. We’re dedicated to promoting the economic benefits of life science business and research for Washington state's economy and patients around the world. We Work For Health seeks to educate our elected leaders, the news media and the communities they serve about these key contributions of the life science sector in our state.
- Innovation and Impact: Roundtable Discussion with Senator Patty MurrayApril 23, 2014
On April 23, U.S. Senator Patty Murray, Washington State University President Dr. Elson Floyd, University of Washington President Michael K. Young, and other Washington state academic and life sciences business leaders joined a forum hosted at Seattle Children’s Research Institute to discuss a new study on the economic benefits of partnerships between the life sciences industry and academic research institutions. The event hosted more than 70 individuals, including key stakeholders in economic development, patient advocacy and private-sector life science enterprises.
- Roundtable with Congressman Adam SmithMarch 18, 2014
The Washington Council on International Trade hosted a discussion on the Trans-Pacific Partnership (TPP) free trade agreement currently under negotiation between the United States and eleven other Asian Pacific economies. Congressman Adam Smith (WA-09) discussed TPP and the benefits its implementation would have for Washington state's international competitiveness.
Completing the TPP trade negotiations is a top priority for Washington elected and business leadership, as Asia is a primary market for Washington exports. TPP would lower barriers to trade and implement uniform regulations and fair intellectual property protection. The passage of TPP would help foster growth and innovation in Washington state's life sciences sector.
May 6, 2016
By Taylor Soper
Seattle-based AVM Biotechnology is raising more cash for its technology that helps improve stem cell delivery.
AVM executive Michael Kuran confirmed an SEC filing that shows the company in the process of raising a $17.5 million round, but wouldn’t provide further details about investors or how the money will be used.
Founded in 2008 and led by CEO Theresa Deisher, AVM is not a stem cell company, but rather a “regenerative medicine company whose technologies optimize the biodistribution and clinical utility of exogenously delivered stem cells and naturally-occurring endogenous stem cells.”
The company employs fewer than 10 people and has raised just under $5 million to date. It’s one of about 800 life sciences companies in Washington state that employ nearly 100,000 people. There were more than $3 billion in life science transactions in 2015 in Washington state, up from $1.6 billion in 2014. Companies such as Juno Therapeutics, Adaptive Biotechnologies and organizations such as the University of Washington and the Fred Hutchinson Cancer Research Center are giving the industry new weight.
May 6, 2016
By Coral Garnick
Genetic Engineering & Biotechnology News, an industry trade publication known as GEN, came out with its annual list of the nation's top biotech clusters, and Seattle came in at No. 7 for the second year in a row.
GEN ranks regions based on five criteria: National Institutes of Health funding, venture capital funding information that was made publicly available through MoneyTree reports, patents, lab space calculated by the commercial real estate brokerage JLL and jobs, also based on JLL’s report.
No. 5 in NIH funding — 219 awards, totaling $218 million
No. 6 in VC funding — $253 million in 11 deals, skewed by a single $195 million financing round won by Adaptive Biotechnologies in May.
No. 8 in patents — 1,763
No. 9 in lab space — 4.5 million square feet
No. 11 in jobs — 23,922 according to JLL
May 6, 2016
By Rachel Neilson
The incoming CEO of Life Science Washington said she wants to diversify the companies on the trade association’s membership rolls.
Leslie Alexandre, who takes over from an interim CEO on May 31, said there are companies and organizations with life-science aspects to their activities that might not consider themselves potential members of the association – but should.
Alexandre said she wants to include agriculture, animal health and ocean science companies as members.
“There are so many companies working in those spaces who probably don’t even know that there’s a fit for them, there’s a home for them in Life Science Washington,” Alexandre said.
“I would like to broaden the scope of what we do,” she said. “There’s been a huge emphasis on human health, which is incredibly important, but we have other industries in this state that we want to make sure are being brought in and included in the scope of the programming and the activities that we provide as a trade association."
Alexandre is joining Life Science Washington from Georgia Cancer Center at Augusta University in Augusta, Georgia, where she has been director of the Office of Research Development and Collaboration for the past four years.
Her earlier work included five years as CEO of the North Carolina Biotechnology Center in that state’s Research Triangle Park, home to high-tech companies and cutting-edge research.
Life Science Washington, which has 700 members, bills itself as the state’s biotechnology and medical company association. It offers to its members consulting services ranging in topic from company formation to merger and acquisition strategy. Since 2011, almost 400 companies have used its consulting services, its spokeswoman said.
It also promotes government policies friendly to life science businesses and helps companies commercialize their products.
Alexandre is succeeding Life Science Washington chairman John Wecker, who has been interim CEO since former CEO Chris Rivera stepped down in January to take a job in the private sector.
The transition at the organization comes at a key moment for life sciences in Washington, with Gov. Jay Inslee announcing in April the creation of a Life Science and Global Health Workforce Panel to strengthen and expand the sector in the state.
Rachel Nielsen covers technology and biotechnology for the Puget Sound Business Journal.
May 2, 2016
By Rachel Neilson
Seattle Genetics (Nasdaq: SGEN) is undergoing some major expansion plans for its core products.
The Bothell company currently has just one commercialized drug, its cancer-fighting Adcetris, which is largely used to treat lymphomas. But it is pursuing additional uses of Adcetris while doing research on another 12 drugs.
The expansion of its drug pipeline could make Seattle Genetics, already a heavyweight in the region's biotech community with 800 employees, into an even bigger company. As it grows, the company helps attract and retain talented cancer researchers to the region, which has become one of the country's hot spots for cancer treatment and disease research.
In its earnings report last week, CEO Clay Siegall highlighted Phase 3 trials that are designed to support additional uses of Adcetris. Phase 3 trials are given to large groups of people to confirm a drug’s effectiveness and monitor side effects.
One of those Adcetris trials, which is for patients with relapsed cutaneous T-cell lymphoma, will report data in the third quarter. In total, Adcetris is being tested in more than 70 trials.
The company is in various stages with the other 12 drugs it has in its pipeline. It plans to start a Phase 3 trial to test its 33A drug against acute myeloid leukemia by the third quarter. Later this year it also expects to report data from 33A Phase 1 trials, in which researchers test a new drug in a small group of people for the first time to evaluate its safety.
Some of the drugs in its pipeline are targeted at solid tumors, particularly bladder cancer. The company has had two such drugs in Phase 1 clinical trials, and it will report data from those trials in early June at the American Society of Clinical Oncology’s annual meeting in Chicago.
Seattle Genetics has the money to maintain such a pipeline. As a publicly traded company with $690 million in cash and investments as of the end of March and no debt, Seattle Genetics is in a “strong financial position,” CEO Clay Siegall said in statement.
April 26, 2016
By Mark Grayson
Today is World Intellectual Property Day, a celebration across the globe of the protections that allow creativity, risk-taking and innovation to thrive. America has long been the world’s innovation center – whether that is in manufacturing, technology or biopharmaceuticals. And it has been shown time and time again that strong protection of intellectual property (IP) is good for patients as it leads to the creation of innovative medicines and lifesaving cures.
Strong IP protections are critical to not only the creation of new drugs, but also to increased patient access to lifesaving drugs in markets throughout the world. Robust, effective approaches to IP encourage the development of new drugs that, after a period of time for further investment in R&D, can then be produced as generics.
Patents are important protections for innovators, investors and entrepreneurs. New medicines, especially, require years of research and billions of dollars before they can even reach patients. These protections are necessary to protect the investment, allowing companies to recoup costs and then further invest in R&D.
Protecting patents is also vital to protecting life sciences innovation. The incentives given to investors and researchers catalyze the creation of new medicines and spur discovery. Just the other week, the Information Technology and Innovation Foundation (ITIF) found that IP protections are crucial to stimulating innovation and improving lives.
In their study, the ITIF found that strong IP protections have extended the world’s average life expectancy, created strong industries and supported the development of lifesaving medicines. The study notes that more chemical entities have been introduced in the United States in the 2000s than the next five countries combined. This is due to the commitment America has made to the biopharmaceutical industry and the innovation economy.
This World IP Day, we hope America continues their commitment to the life sciences industry and the advancement of new treatments. As long as protections exist for innovators, the United States will continue to lead the world in creating innovative, lifesaving medicines.
- 1,704 vendor relationships
- $433,366,284 vendor spending
- #DYK in the age of personalized medicine, biomarkers are emerging as important tools in drug development? Learn more https://t.co/GMdjXXaasw
15 hours ago
- RT @PhRMA: Biomarkers and surrogate endpoints can help allow patients quicker access to medicines https://t.co/6N9EzbkkdF
17 hours ago
- RT @fredhutch: "#Malaria ends with me." Zambia's call to action goes beyond Zambia, beyond Africa. Malaria ends with us. @PATHtweets #bfgh
2 days ago
Northeastern University – Seattle is Washington’s first private research university and provides the region with talent, partnerships, and a strong knowledge base.Learn More
Specializing in small molecules, biopharmaceuticals, chemicals, medical devices, and veterinary products, MPI Research is the largest single-site preclinical CRO facility in the world – with more than 1 million square feet and nearly 600 animal rooms.Learn More